Showing results (161-170 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|September 13, 2015
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trialSusanna Hegewisch-Becker, Ullrich Graeven, Christian A Lerchenmüller, et al.
The Lancet. Oncology|September 16, 2015
Inherited cylindromas: lessons from a rare tumourNeil Rajan, Alan Ashworth
The Lancet. Oncology|October 18, 2015
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trialR Paul Symonds, Charlie Gourley, Susan Davidson, et al.
The Lancet. Oncology|October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trialEdith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
The Lancet. Oncology|February 13, 2016
Rare cancers: a sea of opportunityNiki Boyd, Janet E Dancey, C Blake Gilks, et al.
The Lancet. Oncology|April 13, 2016
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trialOlivier Mir, Claire Cropet, Maud Toulmonde, et al.
The Lancet. Oncology|December 3, 2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialKarim Fizazi, Lance Pagliaro, Agnes Laplanche, et al.
The Lancet. Oncology|December 3, 2014
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trialIvana Sestak, Shalini Singh, Jack Cuzick, et al.
The Lancet. Oncology|December 3, 2014
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trialsHans-Joachim Schmoll, Chris Twelves, Weijing Sun, et al.
The Lancet. Oncology|December 3, 2014
High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancerDirk De Ruysscher, Corinne Faivre-Finn, Cecile Le Pechoux, et al.
Pageof 336